The results reported herein establish a basis forthe development of new inhibitors blocking the binding of TSC2 andRheb, aiming to reinstate mTORC1 activation and facilitate improvedefficacy of PIs against multiple myeloma. This evidence concerns the gene TSC2 and AL amyloidosis.